Company news

Biogen Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025

July 31, 2025

New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease

July 30, 2025

Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC

July 30, 2025

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression

July 25, 2025

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025

July 21, 2025

Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary

July 20, 2025

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

July 17, 2025

The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association

July 16, 2025

Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors

July 15, 2025

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

July 9, 2025

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

June 29, 2025

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

June 27, 2025

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

June 24, 2025

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

June 17, 2025

Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer

June 17, 2025

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

May 26, 2025

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

April 14, 2025

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

April 1, 2025

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

March 23, 2025

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

March 10, 2025

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

February 17, 2025

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

January 30, 2025

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

January 25, 2025

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

January 25, 2025

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

January 22, 2025

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

January 12, 2025

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen

January 9, 2025

"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico

December 3, 2024

"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea

November 26, 2024

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

November 13, 2024

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

October 28, 2024

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

October 28, 2024

Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

October 27, 2024

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

October 25, 2024

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

October 23, 2024

Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024

October 21, 2024

Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients

October 8, 2024

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

October 7, 2024

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

September 23, 2024

Biogen Board Appoints Two New Independent Directors

September 11, 2024

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

September 3, 2024

Leqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

August 21, 2024

New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Alzheimer's Association International Conference (AAIC...

July 29, 2024

New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC...

July 29, 2024

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

July 29, 2024

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

July 25, 2024

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor

July 23, 2024

Biogen Completes Acquisition of Human Immunology Biosciences

July 1, 2024

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China

June 26, 2024

TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union

June 23, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 55 decks. Every deck is listed under its year.